The Neurocognitive Sub-study of Encore1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to investigate whether HIV and HIV medication can affect certain areas of brain function. This study will look at possible changes in brain function including memory, concentration and thought processes to see if there are any differences between the two doses of efavirenz used in the Encore1 study and also the level of efavirenz in the blood

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

NCT01271894

HIV Infection

COMPLETED PHASE3

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

NCT03567304

HIV-1-infection Neurocognitive Dysfunction

UNKNOWN PHASE4

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects

NCT02042001

Impaired Cognition Depression/Anxiety Poor Quality Sleep +2 more

COMPLETED PHASE4

COMO: Cognition Study With HIV+ Patients (CTNPT 015)

NCT02144688

HIV - Human Immunodeficiency Virus Cognitive Symptoms

TERMINATED EARLY_PHASE1

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

NCT01978743

HIV HIV-associated Neurocognitive Disorder Neurotoxicity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reduced dose Efavirenz arm

Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).

Group Type EXPERIMENTAL

Efavirenz

Intervention Type DRUG

400mg qd; 2 x 200mg

Normal Efavirenz dose arm

Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)

Group Type ACTIVE_COMPARATOR

Efavirenz

Intervention Type DRUG

600mg qd; 3 x 200mg qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Efavirenz

400mg qd; 2 x 200mg

Intervention Type DRUG

Efavirenz

600mg qd; 3 x 200mg qd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All subjects entering into the main study protocol at participating centres will be eligible to enter this sub-study.

Exclusion Criteria

* Existing neurological brain disease
* Recent (\<6months ) head injury
* Current major depression or psychosis
* Current alcohol abuse
* Intended use of recreational drugs during study period
* Uncontrolled medical conditions deemed to potentially interfere with cognitive function (e.g. uncontrolled diabetes, pyrexial illness, uraemia etc)

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No